Julie Milia

4.8k total citations · 1 hit paper
23 papers, 1.3k citations indexed

About

Julie Milia is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Julie Milia has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Julie Milia's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (9 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Julie Milia is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (9 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Julie Milia collaborates with scholars based in France, Switzerland and United States. Julie Milia's co-authors include Julien Mazières, Fabrice Barlési, Isabelle Rouquette, Michèle Beau‐Faller, Oliver Gautschi, Benjamin Besse, Alexis B. Cortot, Solange Peters, Denis Moro‐Sibilot and Éric Dansin and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Julie Milia

23 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

2013 489 citations Julien Mazières, Solange Peters et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Milia France	14	992	972	352	267	131	23	1.3k
Satoru Kitazono Japan	23	833 0.8×	1.0k 1.0×	349 1.0×	252 0.9×	113 0.9×	92	1.5k
Dana Ghiorghiu United Kingdom	15	929 0.9×	808 0.8×	497 1.4×	171 0.6×	139 1.1×	36	1.4k
Rocco Sacco Italy	11	877 0.9×	658 0.7×	392 1.1×	255 1.0×	89 0.7×	12	1.2k
Akito Hata Japan	25	1.4k 1.4×	1.1k 1.1×	320 0.9×	325 1.2×	62 0.5×	117	1.7k
Siddhartha Devarakonda United States	15	801 0.8×	649 0.7×	484 1.4×	488 1.8×	83 0.6×	56	1.3k
Vincent O’Neill United States	8	620 0.6×	895 0.9×	477 1.4×	303 1.1×	56 0.4×	28	1.2k
Jaromı́r Roubec Czechia	9	1.3k 1.3×	1.3k 1.3×	574 1.6×	170 0.6×	41 0.3×	23	1.7k
Marta Jimenez France	13	944 1.0×	888 0.9×	360 1.0×	415 1.6×	97 0.7×	51	1.4k
Deborah Ricci United States	15	399 0.4×	474 0.5×	261 0.7×	262 1.0×	68 0.5×	51	876
Reiko Kaji Japan	20	1.0k 1.0×	793 0.8×	236 0.7×	249 0.9×	39 0.3×	44	1.2k

Countries citing papers authored by Julie Milia

Since Specialization

Citations

This map shows the geographic impact of Julie Milia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Milia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Milia more than expected).

Fields of papers citing papers by Julie Milia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Milia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Milia. The network helps show where Julie Milia may publish in the future.

Co-authorship network of co-authors of Julie Milia

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Milia. A scholar is included among the top collaborators of Julie Milia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Milia. Julie Milia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Prévôt, Grégoire, Bastien Cabarrou, Olivier Calvayrac, et al.. (2022). Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease. Respiratory Medicine and Research. 83. 100946–100946. 4 indexed citations

Jeanson, A., Pascale Tomasini, M. Souquet-Bressand, et al.. (2019). Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(6). 1095–1101. 171 indexed citations

Rouquette, Isabelle, Julia Gilhodes, M.V. Bluthgen, et al.. (2019). Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomarker Research. 7(1). 28–28. 32 indexed citations

Mhanna, Laurent, Nicolas Guibert, Julie Milia, & Julien Mazières. (2019). When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology. 20(7). 60–60. 29 indexed citations

Delaunay, Myriam, Philippe Caron, V. Sibaud, et al.. (2018). Toxicité des inhibiteurs de points de contrôle immunitaires. Revue des Maladies Respiratoires. 35(10). 1028–1038. 11 indexed citations

Mhanna, Laurent, Julie Milia, S. Couraud, et al.. (2018). Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.. Journal of Clinical Oncology. 36(5_suppl). 172–172. 22 indexed citations

Drilon, Alexander, Thomas Filleron, Isabella Bergagnini, et al.. (2017). Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers.. Journal of Clinical Oncology. 35(15_suppl). 9069–9069. 7 indexed citations

Milia, Julie, T. Barnes, Oliver Gautschi, et al.. (2017). Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.. Journal of Clinical Oncology. 35(15_suppl). 9071–9071. 12 indexed citations

Ung, Mony, Isabelle Rouquette, Thomas Filleron, et al.. (2016). Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. Clinical Lung Cancer. 17(5). 391–397. 71 indexed citations

10.

Calvayrac, Olivier, Julien Mazières, Claire Marty‐Detraves, et al.. (2016). The RAS ‐related GTP ase RHOB confers resistance to EGFR ‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT ‐dependent mechanism. EMBO Molecular Medicine. 9(2). 238–250. 25 indexed citations

11.

Gautschi, Oliver, Juergen Wolf, Julie Milia, et al.. (2016). Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.. Journal of Clinical Oncology. 34(15_suppl). 9014–9014. 9 indexed citations

12.

Mazières, Julien, Fabrice Barlési, Thomas Filleron, et al.. (2015). Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of Oncology. 27(2). 281–286. 219 indexed citations

13.

Gautschi, Oliver, M.V. Bluthgen, Egbert F. Smit, et al.. (2015). Targeted Therapy for Braf-Mutant Lung Cancer: Results from the European Euraf Cohort Study. Annals of Oncology. 26. i57–i57. 2 indexed citations

14.

Rouvière, Damien, et al.. (2015). Nouvelles cibles et nouvelles molécules en oncologie thoracique. Revue des Maladies Respiratoires. 32(8). 867–876. 4 indexed citations

15.

Calvayrac, Olivier, Anne Pradines, Isabelle Raymond‐Letron, et al.. (2014). RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer. Clinical Cancer Research. 20(24). 6541–6550. 18 indexed citations

16.

Mazières, Julien, Jean-Louis Pujol, Nikos Kalampalikis, et al.. (2014). Perception of Lung Cancer among the General Population and Comparison with Other Cancers. Journal of Thoracic Oncology. 10(3). 420–425. 24 indexed citations

17.

Mazières, Julien, Isabelle Rouquette, Benoît Lepage, et al.. (2013). Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked. Journal of Thoracic Oncology. 8(7). 923–929. 47 indexed citations

18.

Mazières, Julien, Solange Peters, Benoît Lepage, et al.. (2013). Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. Journal of Clinical Oncology. 31(16). 1997–2003. 489 indexed citations breakdown →

19.

Rouquette, Isabelle, Valérie Lauwers‐Cancès, L. Brouchet, et al.. (2011). Characteristics of lung cancer in women: Importance of hormonal and growth factors. Lung Cancer. 76(3). 280–285. 37 indexed citations

20.

Milia, Julie, Florence Dalenc, Isabelle Ader, et al.. (2005). Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death and Differentiation. 12(5). 492–501. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact